To establish a national population-based registry of men who have been diagnosed with prostate cancer, to provide a baseline of key prostate cancer health outcomes indicators and evidence-based data to help deliver improved quality of treatment and care and provide clinicians with risk adjusted feedback on their patients.

To support the implementation of outside the box proof of concept ideas that disrupt long held assumptions/myths about men and their health which will encourage doing things differently and ultimately lead to improved health outcomes.

To support transformational prostate cancer research that will accelerate progress towards the reduction of death and suffering due to recurrent or advanced prostate cancer.

To trial a national program of Prostate Cancer Specialist Nurses working within the hospital system to provide supportive care for men affected by prostate cancer.

To make discoveries which will improve the length and quality of life of men with prostate cancer, especially prostate cancer which cannot be cured by surgery or radiation therapy.

This project sought to establish guidelines and identify key attributes for providers and registry leaders to consider when selecting an electronic tool for collecting data directly from patients regarding their health (i.e. patient-reported outcomes PROMs), to develop a decision framework for selecting the right tool for a given setting and/or context, and summarize information on the most popular tools to facilitate comparison and selection.

To reduce the impact of cancer in the community and improve outcomes for people affected by cancer.To work collaboratively with organisations that support cancer research to generate evidence, increase knowledge, and improve the translation of research into policy and practice.

To define a minimum set of localised prostate cancer health outcome indicators and their measurement to foster research and reporting around the world. The project is looking at the outcomes that matter most to men with localised prostate cancer, and standardising the datapoints and collection method. This will lead to better reporting and research, which will foster changes in practice, improving the outcomes for men who have been diagnosed with localised prostate cancer.

To define a minimum set of health outcome indicators and their measurement that are the most important to collect in the clinic, and in follow up treatment for men who have advanced prostate cancer. Standardising this and the collection method will lead to better reporting and research, which will foster changes in practice, improving the outcomes for men who have been diagnosed with advanced disease.

To identify those prostate cancer patients in an intermediate stage of cancer spread who will benefit from radical treatment of their primary tumour and metastases based on shared biological characteristics.

To identify those prostate cancer patients in an intermediate stage of cancer spread who will benefit from radical treatment of their primary tumour and metastases based on shared biological characteristics.

To identify those prostate cancer patients in an intermediate stage of cancer spread who will benefit from radical treatment of their primary tumour and metastases based on shared biological characteristics.

To identify those prostate cancer patients in an intermediate stage of cancer spread who will benefit from radical treatment of their primary tumour and metastases based on shared biological characteristics.

To identify those prostate cancer patients in an intermediate stage of cancer spread who will benefit from radical treatment of their primary tumour and metastases based on shared biological characteristics.

To identify those prostate cancer patients in an intermediate stage of cancer spread who will benefit from radical treatment of their primary tumour and metastases based on shared biological characteristics.

To identify those prostate cancer patients in an intermediate stage of cancer spread who will benefit from radical treatment of their primary tumour and metastases based on shared biological characteristics.